Arcadia Biosciences (NASDAQ:RKDA) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued to investors on Friday. The brokerage issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $6.00 price target on shares of Arcadia Biosciences in a research note on Wednesday, August 21st.

Arcadia Biosciences Price Performance

Arcadia Biosciences stock opened at $2.92 on Friday. The company has a market cap of $3.98 million, a price-to-earnings ratio of -0.57 and a beta of 1.34. The firm has a 50-day moving average of $2.84 and a 200-day moving average of $2.68. Arcadia Biosciences has a one year low of $1.85 and a one year high of $4.19.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. The company had revenue of $1.31 million for the quarter, compared to analyst estimates of $0.95 million. During the same period last year, the company posted ($2.64) earnings per share. As a group, sell-side analysts expect that Arcadia Biosciences will post -1.7 earnings per share for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.